Barclays Maintains Overweight on AbbVie, Raises Price Target to $175
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has maintained an Overweight rating on AbbVie (NYSE:ABBV) and increased the price target from $170 to $175.
January 23, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has maintained an Overweight rating on AbbVie and raised the price target to $175, indicating a positive outlook on the stock.
The increase in price target by a major analyst like Barclays suggests a strong confidence in AbbVie's future performance. This typically leads to increased investor interest and can drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100